Terms: = Kidney tumors AND PSA AND Treatment
125 results:
1. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
2. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.
Falagario UG; Abbadi A; Remmers S; Björnebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
JAMA Netw Open; 2023 Sep; 6(9):e2332900. PubMed ID: 37695584
[TBL] [Abstract] [Full Text] [Related]
3. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Michalski JM; Winter KA; Prestidge BR; Sanda MG; Amin M; Bice WS; Gay HA; Ibbott GS; Crook JM; Catton CN; Raben A; Bosch W; Beyer DC; Frank SJ; Papagikos MA; Rosenthal SA; Barthold HJ; Roach M; Moughan J; Sandler HM
J Clin Oncol; 2023 Aug; 41(24):4035-4044. PubMed ID: 37315297
[TBL] [Abstract] [Full Text] [Related]
4. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
[TBL] [Abstract] [Full Text] [Related]
5. Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results.
Francolini G; Ganovelli M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L
Clin Exp Metastasis; 2023 Apr; 40(2):197-201. PubMed ID: 37012498
[TBL] [Abstract] [Full Text] [Related]
6. Active surveillance in renal transplant patients with prostate cancer: a multicentre analysis.
Soeterik TFW; van den Bergh RCN; van Melick HHE; Kelder H; Peretti F; Dariane C; Timsit MO; Branchereau J; Mesnard B; Tilki D; Olsburgh J; Kulkarni M; Kasivisvanathan V; Breda A; Biancone L; Gontero P; Gandaglia G; Marra G;
World J Urol; 2023 Mar; 41(3):725-732. PubMed ID: 36710292
[TBL] [Abstract] [Full Text] [Related]
7. Can We Identify Patients in Danger of Delayed treatment? Management of COVID-19 Pandemic Backlog in Urology Care in Poland.
Ratajczak JM; Gawrońska A; Fischer M; Hladun T; Marczak M
Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554427
[TBL] [Abstract] [Full Text] [Related]
8. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S
Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504
[TBL] [Abstract] [Full Text] [Related]
9. Hematologic toxicity profile and efficacy of [
Lawal IO; Morgenstern A; Vorster M; Knoesen O; Mahapane J; Hlongwa KN; Maserumule LC; Ndlovu H; Reed JD; Popoola GO; Mokoala KMG; Mdlophane A; Bruchertseifer F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3581-3592. PubMed ID: 35384462
[TBL] [Abstract] [Full Text] [Related]
10. Prostatic Schwannoma Presenting with Prostate-specific Antigen Elevation: A Case Report.
Lai BCH; Shih HJ; Syu SH; Lin KH
Yale J Biol Med; 2021 Dec; 94(4):609-612. PubMed ID: 34970099
[No Abstract] [Full Text] [Related]
11. psa and psa Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
Crocerossa F; Carbonara U; Parekh J; Urdaneta A; Weprin S; Damiano R; Grob MB; Hampton LJ; Paul A; Autorino R; Cantiello F
Urol Int; 2022; 106(9):920-927. PubMed ID: 34933313
[TBL] [Abstract] [Full Text] [Related]
12. Exosomal long noncoding RNA HOXD-AS1 promotes prostate cancer metastasis via miR-361-5p/FOXM1 axis.
Jiang Y; Zhao H; Chen Y; Li K; Li T; Chen J; Zhang B; Guo C; Qing L; Shen J; Liu X; Gu P
Cell Death Dis; 2021 Dec; 12(12):1129. PubMed ID: 34864822
[TBL] [Abstract] [Full Text] [Related]
13. Assessment of oncological and functional outcomes of retropubic radical prostatectomy: An academic center experience.
Prudhomme T; Roumiguié M; Péricart S; Doumerc N; Lesourd M; Patard PM; Gamé X; Soulié M; Thoulouzan M
Prog Urol; 2021 Dec; 31(16):1123-1132. PubMed ID: 34565670
[TBL] [Abstract] [Full Text] [Related]
14. The Role of C-Reactive Protein in kidney, Bladder, and Prostate Cancers.
O'Brian D; Prunty M; Hill A; Shoag J
Front Immunol; 2021; 12():721989. PubMed ID: 34512646
[TBL] [Abstract] [Full Text] [Related]
15. [Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer].
Bai GC; Song Y; Jin J; Yu W; He ZS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):686-691. PubMed ID: 34393229
[TBL] [Abstract] [Full Text] [Related]
16. Radical prostatectomy outcomes in renal transplant recipients: a retrospective case series of Thai patients.
Sirisopana K; Jenjitranant P; Sangkum P; Kijvikai K; Pacharatakul S; Leenanupunth C; Kochakarn W; Kongchareonsombat W
BMC Urol; 2021 Jul; 21(1):97. PubMed ID: 34229680
[TBL] [Abstract] [Full Text] [Related]
17. [A Case of Robot-Assisted Radical Cystoprostatectomy for Locally Advanced Prostate Cancer with Bladder Infiltration].
Sasaki Y; Kadoriku F; Fukatani Y; Yamamoto H; Daizumoto K; Ozaki K; Ueno Y; Tsuda M; Kusuhara Y; Fukawa T; Yamamoto Y; Yamaguchi K; Takahashi M; Kanayama H
Hinyokika Kiyo; 2021 Apr; 67(4):163-166. PubMed ID: 34107613
[TBL] [Abstract] [Full Text] [Related]
18. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
Campbell SR; Tom MC; Agrawal S; Efstathiou JA; Michalski JM; Abramowitz MC; Pollack A; Spratt DE; Hearn JWD; Stephans KL; Gao T; Li J; Tendulkar RD
Eur Urol Oncol; 2022 Jun; 5(3):304-313. PubMed ID: 34016556
[TBL] [Abstract] [Full Text] [Related]
19. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract] [Full Text] [Related]
20. Primary prostate cancer synchronous with renal cell carcinoma: clinical experience and literature review.
Li ZY; Ying CC; Wan ZH; Wang ZS; Li GH; Chen L; Guo YL
Rom J Morphol Embryol; 2020; 61(2):555-561. PubMed ID: 33544809
[TBL] [Abstract] [Full Text] [Related]
[Next]
